I Tried It Anyway." NYC Patients Navigate the New World of Peptide Therapy Patient accounts in this article are based on real DripGym patient experiences
O., Fieger-Bschges, H., Ruus, P., Nowak, H., Riethmller-Winzen, H., Peukert, M., & Blume, H
Semaglutide is a GLP-1 receptor agonist that primarily acts on receptors in the brain (appetite regulation), pancreas (insulin secretion), and gastrointestinal tract (gastric emptying)
Optimal technique with a well-formulated product might achieve 30-40%
Additionally, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial demonstrated that semaglutide consistently reduced major cardiovascular event endpoints by approximately 20% compared to placebo over an approximately 3-year follow-up period in patients with overweight or obesity and cardiovascular disease (Table 1), but without diabetes [93]
Novo Nordisk, the manufacturer of Wegovy and Ozempic, reported $31.1 billion in combined revenue from these three products in 2024, according to Pew Research Center data
